Phlebodia 600,600 mg 15 pcs.

The drug Phlebodia 600 has a phlebotonic effect (reduces the stretching of veins, increases the tone of the veins (dose-dependent effect), reduces venous congestion), improves lymphatic drainage (increases the tone and frequency of contraction of the lymph capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases capillary resistance (dose-dependent effect), decreases their permeability), reduces leukocyte adhesion to the venous wall and their migration into the paravenous tissue, improves oxygen diffusion and perfusion in the skin tissue, has anti-inflammatory effect.

It enhances the vasoconstrictor effect of adrenaline, noradrenaline, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane.

Pharmacokinetics

It is rapidly absorbed from the gastrointestinal tract, found in plasma 2 hours after ingestion. Maximum plasma concentration is reached 5 hours after ingestion.

It is evenly distributed and accumulated in all layers of the wall of the hollow veins and subcutaneous veins of the lower extremities, to a lesser extent in the kidneys, liver and lungs and other tissues.

The selective accumulation of diosmin and/or its metabolites in the venous vessels reaches a maximum by 9 hours after administration and persists for 96 hours. It is excreted by the kidneys 79%, by the intestine – 11%, with the bile – 2.4%.

Indications

As part of the complex therapy:

Active ingredient

Composition

1 film-coated tablet contains:

the active substance:

diosmin (in terms of dry substance) 600 mg,

excipients:

talc, 10.24 mg;

colloidal silicon dioxide, 3.5 mg;

stearic acid – 50.05 mg;

MCC – up to 910 mg,

coating film:

Sepiphilm 002 (hypromellose (E464) – 9.832 mg, MCC – 7.866 mg, macrogoal 8 stearate type 1 – 1.967 mg); Sepispers AP 5523 pink (propylene glycol – traces, hypromellose (E464) – 0.458 mg, titanium dioxide (E171) – 4.026 mg, dye crimson [Ponceau 4R] (E124) – 0.401 mg, iron oxide black (E172) – 0.13 mg, iron oxide red (E172) – 0.02 mg); Opaglos 6000 (carnauba wax (E903) – 0.075 mg, beeswax (E901) – 0.075 mg, shellac (E904) – 0.15 mg, ethanol 95° – traces),

How to take, the dosage

Physician should be consulted before using the drug.

The drug is intended to be taken orally.

In case of varicose veins of the lower limbs and chronic lymphovenous insufficiency (edema, pain, cramps), I tablet daily in the morning on an empty stomach is prescribed.

The duration of therapy is usually 2 months. In exacerbation of hemorrhoids, the drug is prescribed 2-3 tablets per day with meals for 7 days. If one or more doses of the drug are missed it is necessary to continue using the drug as usual and in the usual dose.

Interaction

No clinically significant effects of interaction with other drugs have been described.

Special Instructions

The treatment of an acute attack of hemorrhoids is carried out in conjunction with other drugs; in the absence of rapid clinical effect, further examination and adjustment of the therapy should be carried out.

Impact on the ability to drive vehicles. There are no data on the negative effect of the drug on the ability to drive vehicles and other mechanisms.

Contraindications

Side effects

In rare cases – hypersensitivity to the drug components (requiring a break in treatment).

Gastrointestinal disorders: dyspeptic disorders (heartburn, nausea, abdominal pain).

CNS disorders: headache.

If any of the side effects listed in the description worsen, or if the patient notices any other side effects not listed in the description, the physician should be informed.

Pregnancy use

To date in clinical practice, there have been no reports of any side effects when using the drug in pregnant women. Use during pregnancy in the second and third

trimesters is possible only by prescription when the expected benefits to the mother exceed the potential risk to the fetus.

There have been no teratogenic effects on the fetus in experimental studies. Administration of the drug is not recommended during breastfeeding because there is no data on penetration of the drug into the breast milk.

Similarities